| 1 | Psoriasis vulgaris (PheCode 696.41) | GCST90476190 | 70.11 |
| 2 | Psoriasis and related disorder (PheCode 696) | GCST90476186 | 68.40 |
| 3 | Psoriasis (PheCode 696.4) | GCST90476187 | 66.67 |
| 4 | Psoriatic arthritis | GCST90243956 | 66.26 |
| 5 | CXCL9 levels | GCST90468935 | 62.05 |
| 6 | Allergic contact dermatitis | FING00000068 | 60.98 |
| 7 | Asthma | Chronic lower respiratory diseases | UKBB00000053 | 60.91 |
| 8 | Nasal polyp | FING00000858 | 60.12 |
| 9 | CD5/TNFRSF9 ratio | GCST90313862 | 59.81 |
| 10 | Asthma-related infections | FING00000118 | 59.42 |
| 11 | Asthma | respiratory | UKBB00000054 | 58.84 |
| 12 | Second line medication for Crohn's disease | FING00001284 | 56.69 |
| 13 | Asthma-related acute respiratory infections | FING00000117 | 56.54 |
| 14 | Asthma/COPD (KELA code 203) | FING00000121 | 54.51 |
| 15 | MS-disease / Multiple Sclerosis | FING00000839 | 54.07 |
| 16 | PALM2 levels | GCST90470152 | 53.86 |
| 17 | Asthma (only as main-diagnosis) (more control exclusions) | FING00000114 | 53.84 |
| 18 | Papulosquamous disorders | FING00001144 | 53.27 |
| 19 | Multiple sclerosis | GCST90475833 | 51.51 |
| 20 | Hypothyroidism | endocrine/metabolic | UKBB00000335 | 51.49 |
| 21 | Suggestive for eosinophilic asthma | FING00001344 | 51.13 |
| 22 | Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditions | UKBB00000518 | 50.34 |
| 23 | Reimbursement for rheumatic diseases | FING00001247 | 50.15 |
| 24 | FCRL6 levels | GCST90469209 | 49.49 |
| 25 | Other hypothyroidism | Disorders of thyroid gland | UKBB00000611 | 49.35 |
| 26 | Chronic lower respiratory diseases | FING00000290 | 49.34 |
| 27 | TNFRSF8 levels | GCST90470915 | 49.26 |
| 28 | Hypothyroidism | GCST90468138 | 48.75 |
| 29 | Hypothyroidism NOS | endocrine/metabolic | UKBB00000336 | 48.57 |
| 30 | TXNL1 levels | GCST90470993 | 47.75 |
| 31 | Hypothyroidism | GCST90204167 | 47.75 |
| 32 | Treatment/medication code - levothyroxine sodium | Medications | UKBB00000849 | 47.42 |
| 33 | Thyroid problems | GCST90475276 | 47.40 |
| 34 | CXCL16 levels | GCST90468928 | 47.33 |
| 35 | Atopic dermatitis | FING00000125 | 47.26 |
| 36 | Asthma (more control exclusions) | FING00000113 | 46.87 |
| 37 | Lymphoid neoplasms (somatic mutation group 2 phenocluster) | GCST90624750 | 46.42 |
| 38 | Autoimmune diseases excluding thyroid diseases | FING00000132 | 45.73 |
| 39 | Rheumatoid arthritis | FING00001267 | 45.61 |
| 40 | Chronic sinusitis | FING00000298 | 45.55 |
| 41 | Autoimmune diseases | FING00000131 | 45.12 |
| 42 | Type 1 diabetes | GCST90000529 | 44.86 |
| 43 | CD48/CRTAM ratio | GCST90313839 | 44.63 |
| 44 | Asthma | GCST90468112 | 44.47 |
| 45 | Psoriasis vulgaris | FING00001224 | 43.60 |
| 46 | Asthma (childhood onset) | GCST007800 | 43.34 |
| 47 | PAFAH1B3 levels | GCST90470145 | 43.12 |
| 48 | Lymphocyte count | GCST90025984 | 42.85 |
| 49 | Atopic dermatitis | GCST90027161 | 42.77 |
| 50 | CRTAM/VCAM1 ratio | GCST90314281 | 42.67 |
| 51 | OSMR levels | GCST90470132 | 42.63 |
| 52 | Asthma | GCST010042 | 42.55 |
| 53 | Disorders of the thyroid gland | FING00000463 | 42.55 |
| 54 | Prescriptions - levothyroxine | thyroid hormone | UKBB00000687 | 42.55 |
| 55 | Prescriptions - thyroid hormone | hormone | UKBB00000705 | 42.55 |
| 56 | Type 1 diabetes | GCST90013791 | 42.36 |
| 57 | Thyroid peroxidase antibody positivity in pregnancy | GCST90435202 | 42.26 |
| 58 | Hypothyroidism NOS (PheCode 244.4) | GCST90475653 | 42.12 |
| 59 | Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044) | GCST90042535 | 41.98 |
| 60 | Psoriasis | GCST90019016 | 41.72 |
| 61 | Thyroid peroxidase antibody levels in pregnancy | GCST90435201 | 41.62 |
| 62 | Hypothyroidism (PheCode 244) | GCST90475647 | 41.40 |
| 63 | Dermatitis and eczema | FING00000402 | 41.36 |
| 64 | Allergic asthma (mode) | FING00000066 | 41.12 |
| 65 | GZMA/GZMB ratio | GCST90315007 | 40.64 |
| 66 | Diseases of hair and hair follicles (PheCode 704) | GCST90476209 | 40.54 |
| 67 | Takes medication for Thyroid problems? | GCST90475277 | 40.45 |
| 68 | Non-cancer illness code, self-reported - eczema/dermatitis | Medical conditions | UKBB00000509 | 40.33 |
| 69 | Asthma | GCST90014325 | 40.29 |
| 70 | Lymphoid neoplasms (B-cell phenocluster) | GCST90624736 | 40.00 |
| 71 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditions | UKBB00000098 | 39.65 |
| 72 | Type 1 diabetes | GCST90014023 | 39.54 |
| 73 | Hypothyroidism | GCST90319320 | 39.10 |
| 74 | NCR1 levels | GCST90470009 | 38.71 |
| 75 | CD5 levels | GCST90468641 | 38.70 |
| 76 | IDO1 levels | GCST90469506 | 38.68 |
| 77 | RBFOX3 levels | GCST90470432 | 38.68 |
| 78 | Eosinophill count | Blood count | UKBB00000206 | 38.59 |
| 79 | CD160/CXCL16 ratio | GCST90313728 | 38.44 |
| 80 | Hypothyroidism, strict autoimmune | FING00000656 | 38.24 |
| 81 | Noninfective enteritis and colitis | FING00000881 | 38.17 |
| 82 | Lymphocyte count | GCST90018742 | 38.13 |
| 83 | Other/unspecified rheumatoid arthritis | FING00001126 | 38.12 |
| 84 | Nasal polyps | respiratory | UKBB00000494 | 37.88 |
| 85 | Lymphoid neoplasms | GCST90624743 | 37.78 |
| 86 | Asthma and allergy | FING00000115 | 37.73 |
| 87 | CD160/KLRB1 ratio | GCST90313731 | 37.70 |
| 88 | Non-cancer illness code, self-reported - asthma | Medical conditions | UKBB00000506 | 37.61 |
| 89 | Asthma (adult onset) | GCST007799 | 37.55 |
| 90 | Basal cell carcinoma (MTAG) | GCST90137411 | 37.15 |
| 91 | Eosinophill percentage (UKB data field 30210) | GCST90468069 | 37.09 |
| 92 | GZMH levels | GCST90469425 | 36.78 |
| 93 | CCL17/PDGFB ratio | GCST90313688 | 36.53 |
| 94 | Asthma | GCST006862 | 36.40 |
| 95 | CD244/CRTAM ratio | GCST90313763 | 36.33 |
| 96 | Thyroid peroxidase antibody positivity with euthyroid in pregnancy | GCST90435203 | 36.31 |
| 97 | Psoriasis | FING00001222 | 35.99 |
| 98 | RPE levels | GCST90470495 | 35.98 |
| 99 | Lymphoid neoplasms (drug group 1 phenocluster) | GCST90624740 | 35.95 |
| 100 | HippSubfield lh volume Hippocampal-tail | GCST90002668 | 35.90 |
| 101 | lymphocyte (absolute count, maximum, inv-norm transformed) | GCST90475423 | 35.80 |
| 102 | Lymphocyte count | GCST90002317 | 35.76 |
| 103 | eosinophil (absolute count, mean, inv-norm transformed) | GCST90475291 | 35.68 |
| 104 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - None of the above | Medical conditions | UKBB00000101 | 35.51 |
| 105 | Pain type(s) experienced in last month - Pain all over the body | Pain | UKBB00000632 | 35.04 |
| 106 | Endometriosis | GCST90018619 | 35.01 |
| 107 | Allergic disease (asthma, hay fever or eczema) | GCST005038 | 34.85 |
| 108 | GZMA/GZMH ratio | GCST90315008 | 34.78 |
| 109 | Eosinophill percentage | Blood count | UKBB00000207 | 34.65 |
| 110 | Eosinophil count | GCST004606 | 34.62 |
| 111 | Graves disease, strict definition | FING00000592 | 34.39 |
| 112 | Coeliac disease | GCST90468120 | 34.26 |
| 113 | lymphocyte (absolute count, mean, inv-norm transformed) | GCST90475426 | 34.17 |
| 114 | eosinophil (absolute count, minimum, inv-norm transformed) | GCST90475294 | 33.96 |
| 115 | CD160/NCR1 ratio | GCST90313732 | 33.96 |
| 116 | Nasal polyps (PheCode 471) | GCST90476019 | 33.83 |
| 117 | Other (seronegative) rheumatoid arthritis, wide | FING00000917 | 33.83 |
| 118 | CRTAM/LY9 ratio | GCST90314278 | 33.82 |
| 119 | Thyrotoxicosis | FING00001360 | 33.77 |
| 120 | eosinophil (absolute count, maximum, inv-norm transformed) | GCST90475288 | 33.72 |
| 121 | Seropositive rheumatoid arthritis, wide | FING00001298 | 33.53 |
| 122 | Childhood asthma (age<16) (more control exclusions) | FING00000270 | 33.51 |
| 123 | Eosinophil percentage of granulocytes | GCST004617 | 33.17 |
| 124 | CD79B/TNFRSF4 ratio | GCST90313903 | 33.01 |
| 125 | Respiratory disease (confirmatory factor analysis Factor 11) | GCST90309345 | 33.01 |
| 126 | Eosinophil percentage of white cells | GCST004600 | 32.87 |
| 127 | Other diseases of upper respiratory tract | FING00001012 | 32.86 |
| 128 | GZMB levels | GCST90469424 | 32.78 |
| 129 | Seropositive rheumatoid arthritis, strict definition | FING00001297 | 32.64 |
| 130 | First line medication for Crohn's disease | FING00000544 | 32.34 |
| 131 | Nasal polyp | Other diseases of upper respiratory tract | UKBB00000493 | 32.33 |
| 132 | Rheumatoid arthritis | GCST90132224 | 32.22 |
| 133 | SKAP1 levels | GCST90470645 | 32.17 |
| 134 | Eosinophil percentage of white cells | GCST90002382 | 31.99 |
| 135 | Eosinophil count | GCST90018733 | 31.79 |
| 136 | Mouth/teeth dental problems - Mouth ulcers | Mouth | UKBB00000488 | 31.60 |
| 137 | Neutrophil percentage of granulocytes | GCST004623 | 31.52 |
| 138 | Crohn disease (strict definition, require KELA, min 2 HDR) | FING00000366 | 31.49 |
| 139 | Eosinophill count (UKB data field 30150) | GCST90468068 | 31.44 |
| 140 | aseg lh volume Hippocampus | GCST90002624 | 31.26 |
| 141 | Sum eosinophil basophil counts | GCST004624 | 31.26 |
| 142 | eosinophil (fraction, minimum, inv-norm transformed) | GCST90475303 | 31.09 |
| 143 | Ceramide (d18:2/22:0) levels | GCST90024682 | 31.03 |
| 144 | Inflammatory bowel disease and other gasteroenteritis and colitis (PheCode 555) | GCST90476065 | 30.71 |
| 145 | ITGAL levels | GCST90469637 | 30.63 |
| 146 | NBN levels | GCST90470002 | 30.61 |
| 147 | Eosinophil count | GCST90002298 | 30.53 |
| 148 | Lymphocyte count | Blood count | UKBB00000411 | 30.52 |
| 149 | Other demyelinating diseases of the central nervous system | FING00000995 | 30.49 |
| 150 | ACYP1 levels | GCST90468214 | 30.39 |
| 151 | TNFRSF17 levels | GCST90470908 | 30.39 |
| 152 | Eosinophil count | GCST90002381 | 30.16 |
| 153 | IL15 levels | GCST90469556 | 30.02 |
| 154 | eosinophil (fraction, maximum, inv-norm transformed) | GCST90475297 | 30.01 |
| 155 | Rheumatoid arthritis | GCST90132223 | 30.00 |
| 156 | Eosinophil count | GCST90002299 | 29.99 |
| 157 | Lymphocyte count (UKB data field 30120) | GCST90468082 | 29.79 |
| 158 | CRTAM/FCRL6 ratio | GCST90314274 | 29.71 |
| 159 | CD160 levels | GCST90468599 | 29.64 |
| 160 | Blood cell traits latent factor 9 (white cell) | GCST90559251 | 29.58 |
| 161 | eosinophil (fraction, mean, inv-norm transformed) | GCST90475300 | 29.46 |
| 162 | Lymphocyte count | GCST90002316 | 29.45 |
| 163 | DTI TBSS L3 Sagittal stratum L | GCST90384555 | 29.35 |
| 164 | Hypothyroidism, drug reimbursement | FING00000655 | 29.29 |
| 165 | Mosaic chromosomal alteration of the X chromosome | GCST90165287 | 29.25 |
| 166 | Allergy/adverse effect of penicillin | injuries & poisonings | UKBB00000028 | 29.17 |
| 167 | LAT/LYN ratio | GCST90315283 | 29.10 |
| 168 | Rheumatoid arthritis | GCST90018690 | 29.09 |
| 169 | Obesity related asthma | FING00000897 | 29.09 |
| 170 | Lymphocyte count | GCST90002388 | 28.97 |
| 171 | lymphocyte (absolute count, minimum, inv-norm transformed) | GCST90475429 | 28.96 |
| 172 | Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers) | FING00000756 | 28.86 |
| 173 | PCBD1 levels | GCST90470166 | 28.75 |
| 174 | Seborrheic dermatitis (PheCode 690.1) | GCST90476171 | 28.75 |
| 175 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Hayfever, allergic rhinitis or eczema | Medical conditions | UKBB00000100 | 28.64 |
| 176 | GZMB/IL15 ratio | GCST90315015 | 28.64 |
| 177 | Psoriasis | GCST90468147 | 28.61 |
| 178 | Left-hemisphere dorsal attention network to amygdala white-matter structural connectivity | GCST90302706 | 28.55 |
| 179 | CD8A levels | GCST90468655 | 28.42 |
| 180 | Hyperthyroidism | GCST90468136 | 28.42 |
| 181 | HLAE/IL15 ratio | GCST90315061 | 28.36 |
| 182 | Eczema | GCST90468126 | 28.34 |
| 183 | BLNK levels | GCST90468448 | 28.17 |
| 184 | MZB1 levels | GCST90469987 | 28.14 |
| 185 | CD6 levels | GCST90468644 | 28.11 |
| 186 | CXCL16/NOTCH1 ratio | GCST90314339 | 28.06 |
| 187 | HSIL lesion of the cervix uteri | FING00000624 | 27.96 |
| 188 | Erythematosquamous dermatosis (PheCode 690) | GCST90476170 | 27.87 |
| 189 | CLC levels | GCST90468762 | 27.69 |
| 190 | Blood cell traits latent factor 17 (white cell) | GCST90559259 | 27.66 |
| 191 | Sarcoidosis | GCST90503483 | 27.49 |
| 192 | Non-cancer illness code, self-reported - hayfever/allergic rhinitis | Medical conditions | UKBB00000513 | 27.44 |
| 193 | Overweight, obesity and other hyperalimentation | endocrine/metabolic | UKBB00000622 | 27.41 |
| 194 | GNLY levels | GCST90469372 | 27.39 |
| 195 | Thyrotoxicosis with diffuse goitre | FING00001361 | 27.31 |
| 196 | PDCD1/TNFRSF8 ratio | GCST90315610 | 27.30 |
| 197 | GNLY/GZMA ratio | GCST90314949 | 27.16 |
| 198 | LTA levels | GCST90469813 | 27.12 |
| 199 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502396 | 27.05 |
| 200 | DTI TBSS MD Superior corona radiata L | GCST90384597 | 26.92 |
| 201 | Type1 diabetes, definitions combined, early onset | FING00001384 | 26.83 |
| 202 | CXCL10 levels | GCST90468923 | 26.79 |
| 203 | Inflammatory bowel disease, strict (require KELA) | FING00000675 | 26.69 |
| 204 | Systemic lupus erythematosus | GCST90011866 | 26.53 |
| 205 | CRTAM levels | GCST90468871 | 26.47 |
| 206 | Lymphocyte count | GCST004627 | 26.43 |
| 207 | LHPP levels | GCST90469768 | 26.35 |
| 208 | PDCD1 levels | GCST90470181 | 26.30 |
| 209 | HSIL lesion of the cervix uteri, vagina or vulva | FING00000625 | 26.25 |
| 210 | CD101 levels | GCST90468596 | 25.90 |
| 211 | Type 1 diabetes | GCST90432066 | 25.87 |
| 212 | HippSubfield lh volume Whole-hippocampus | GCST90002689 | 25.83 |
| 213 | Neurofibromatosis, type 2 | FING00000867 | 25.81 |
| 214 | Asthma | GCST90475259 | 25.72 |
| 215 | Blood cell traits latent factor 3 (white cell) | GCST90559245 | 25.70 |
| 216 | Seronegative rheumatoid arthritis | FING00001296 | 25.44 |
| 217 | Pulmonary fibrosis | GCST90018688 | 25.42 |
| 218 | Primary biliary cholangitis (PBC) | FING00001211 | 25.29 |
| 219 | Polyarthropathies | FING00001180 | 25.15 |
| 220 | Prescriptions - tramadol | opioid analgesic,selective serotonin re-uptake inhibitor,norepinephrine re-uptake inhibitor | UKBB00000706 | 25.14 |
| 221 | Prescriptions - opioid analgesic|selective serotonin re-uptake inhibitor|norepinephrine re-uptake inhibitor | UKBB00000694 | 25.14 |
| 222 | Left-hemisphere control network to amygdala white-matter structural connectivity | GCST90302757 | 25.00 |
| 223 | IL5RA/TNFRSF13B ratio | GCST90315164 | 24.78 |
| 224 | ROR1/THBD ratio | GCST90315786 | 24.78 |
| 225 | S100A11/S100A12 ratio | GCST90315798 | 24.76 |
| 226 | KLRF1 levels | GCST90469712 | 24.75 |
| 227 | ICD10 N84: Polyp of female genital tract | GCST90454216 | 24.74 |
| 228 | Acute upper respiratory infections | FING00000034 | 24.56 |
| 229 | Disorders of orbit | FING00000449 | 24.54 |
| 230 | Asthma with exacerbation (PheCode 495.2) | GCST90476025 | 24.45 |
| 231 | Monoclonal gammopathy of undetermined significance | GCST90624745 | 24.42 |
| 232 | KLRB1 levels | GCST90469709 | 24.37 |
| 233 | HippSubfield lh volume GC-ML-DG-head | GCST90002679 | 24.37 |
| 234 | Infective dermatitis | FING00000673 | 24.26 |
| 235 | SH2B3/TBL1X ratio | GCST90315841 | 24.24 |
| 236 | Primary biliary cholangitis | GCST90061440 | 24.12 |
| 237 | SNRPB2 levels | GCST90470697 | 24.11 |
| 238 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 24.09 |
| 239 | MAVS/TBL1X ratio | GCST90315399 | 23.72 |
| 240 | Asthma | GCST90476024 | 23.71 |
| 241 | Wheeze or whistling in the chest in last year | Breathing | UKBB00000912 | 23.66 |
| 242 | GZMA/TNFRSF8 ratio | GCST90315014 | 23.66 |
| 243 | IL2RB levels | GCST90469586 | 23.61 |
| 244 | KLRK1 levels | GCST90469713 | 23.51 |
| 245 | Iridocyclitis | FING00000696 | 23.48 |
| 246 | KLF4 levels | GCST90469694 | 23.46 |
| 247 | aparc-a2009s rh thickness G-temporal-middle | GCST90003714 | 23.42 |
| 248 | HippSubfield lh volume Whole-hippocampal-body | GCST90002687 | 23.42 |
| 249 | IPCEF1/SERPINE1 ratio | GCST90315184 | 23.38 |
| 250 | PDCD5 levels | GCST90470182 | 23.37 |
| 251 | ELOA/POLR2F ratio | GCST90314643 | 23.30 |
| 252 | DKK1/IPCEF1 ratio | GCST90314471 | 23.30 |
| 253 | Obesity | endocrine/metabolic | UKBB00000544 | 23.19 |
| 254 | Seborrhoeic dermatitis | FING00001282 | 23.18 |
| 255 | Obesity | Obesity and other hyperalimentation | UKBB00000545 | 23.12 |
| 256 | ATOX1/SNAP29 ratio | GCST90313374 | 23.11 |
| 257 | Personal history of allergy to drugs, medicaments and biologocal substances | Persons with potential health hazards related to family and personal history and certain conditions influencing health status | UKBB00000641 | 23.09 |
| 258 | CD244/FCRL6 ratio | GCST90313765 | 23.09 |
| 259 | Rash and other nonspecific skin eruption (PheCode 687.1) | GCST90476167 | 23.07 |
| 260 | Celiac disease (PheCode 557.1) | GCST90044158 | 23.00 |
| 261 | IL1RL1 levels | GCST90469574 | 22.94 |
| 262 | DTI autoptx MD cgc l tract | GCST90385224 | 22.88 |
| 263 | SH3GLB2 levels | GCST90470621 | 22.84 |
| 264 | CD5/IL16 ratio | GCST90313861 | 22.83 |
| 265 | BMP7 levels | GCST90088157 | 22.79 |
| 266 | COPD/asthma/ILD related infections | FING00000353 | 22.77 |
| 267 | Other noninfective gastroenteritis and colitis | FING00001077 | 22.73 |
| 268 | Sicca syndrome [Sjögren] | FING00001304 | 22.66 |
| 269 | Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications | GCST90093113 | 22.65 |
| 270 | Blood cell traits latent factor 12 (red cell) | GCST90559254 | 22.62 |
| 271 | T1 FreeSurfer aseg MaskVol-to-eTIV | GCST90384192 | 22.57 |
| 272 | Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) | GCST90132227 | 22.51 |
| 273 | GZMA/TNFRSF4 ratio | GCST90315013 | 22.51 |
| 274 | KDM3A levels | GCST90469671 | 22.46 |
| 275 | GRAP2/SRC ratio | GCST90314989 | 22.43 |
| 276 | F2R/SNX9 ratio | GCST90314736 | 22.40 |
| 277 | PAG1 levels | GCST90470147 | 22.38 |
| 278 | DNAJC21 levels | GCST90469016 | 22.31 |
| 279 | Hayfever | GCST90468131 | 22.21 |
| 280 | Chronic dermatitis due to solar radiation (PheCode 938.2) | GCST90476288 | 22.14 |
| 281 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 22.07 |
| 282 | Chalazion | FING00000267 | 21.95 |
| 283 | Disorders of sclera, cornea, iris and ciliary body | FING00000458 | 21.88 |
| 284 | Ceramide (d18:2/22:0) levels | GCST90024054 | 21.82 |
| 285 | TRAF2/WWP2 ratio | GCST90315943 | 21.82 |
| 286 | Type 1 diabetes, definitions combined | FING00001380 | 21.72 |
| 287 | Eosinophil count variance | GCST90565689 | 21.71 |
| 288 | HippSubfield lh volume GC-ML-DG-body | GCST90002681 | 21.58 |
| 289 | C5 levels | GCST90468500 | 21.56 |
| 290 | Benign leiomyoma with endometriosis (controls excluding all cancers) | FING00000145 | 21.39 |
| 291 | FCRL5/LY96 ratio | GCST90314803 | 21.36 |
| 292 | CD48/SLAMF7 ratio | GCST90313842 | 21.36 |
| 293 | HippSubfield lh volume CA4-head | GCST90002682 | 21.27 |
| 294 | CRTAP levels | GCST90468872 | 21.26 |
| 295 | Other acute lower respiratory infections | FING00000921 | 21.22 |
| 296 | Inflammatory bowel disease | GCST90432182 | 21.01 |
| 297 | DTI TBSS L3 Cingulum hippocampus R | GCST90384560 | 21.00 |
| 298 | Omega-3 fatty acids to total fatty acids percentage | GCST90502448 | 20.95 |
| 299 | Graves' disease (PheCode 242.1) | GCST90475644 | 20.87 |
| 300 | Wheeze or whistling in the chest in last year (UKB data field 2316) | GCST90043614 | 20.84 |
| 301 | Ulcerative colitis | GCST90018713 | 20.82 |
| 302 | CRTAM/PDCD1 ratio | GCST90314279 | 20.77 |
| 303 | X-21285 levels | GCST90200576 | 20.72 |
| 304 | IL15/IL18BP ratio | GCST90315148 | 20.72 |
| 305 | CRTAM/GZMA ratio | GCST90314275 | 20.72 |
| 306 | DNA methylation PhenoAge acceleration | GCST90014292 | 20.70 |
| 307 | RILP levels | GCST90470471 | 20.62 |
| 308 | SIT1 levels | GCST90470644 | 20.62 |
| 309 | Ulcerative colitis (PheCode 555.2) | GCST90044155 | 20.59 |
| 310 | Peripheral or central vertigo (PheCode 386.2) | GCST90475907 | 20.59 |
| 311 | CD27/DLL1 ratio | GCST90313771 | 20.55 |
| 312 | Lichen sclerosus et atrophicus | FING00000723 | 20.52 |
| 313 | ICD10 N87: Dysplasia of cervix uteri | GCST90454218 | 20.50 |
| 314 | Interpolated Year when non-cancer illness first diagnosed | Medical conditions | UKBB00000371 | 20.48 |
| 315 | HippSubfield lh volume CA4-body | GCST90002683 | 20.42 |
| 316 | Operation code - tonsillectomy +/- adenoids | Operations | UKBB00000567 | 20.32 |
| 317 | Sarcoidosis | FING00001275 | 20.25 |
| 318 | GRHPR levels | GCST90469400 | 20.24 |
| 319 | Asthma-related pneumonia | FING00000119 | 20.23 |
| 320 | Systemic connective tissue disorders | FING00001350 | 20.22 |
| 321 | Smoking status (weighted GWA) | GCST90267303 | 20.22 |
| 322 | Treatment/medication code - ventolin 100micrograms inhaler | Medications | UKBB00000860 | 20.05 |
| 323 | APRT levels | GCST90468345 | 20.03 |
| 324 | CD48/FCRL6 ratio | GCST90313840 | 20.01 |
| 325 | Non-albumin protein levels | UKBB00000503 | 19.99 |
| 326 | IL18 levels | GCST90428411 | 19.93 |
| 327 | Bipolar disorder | GCST003724 | 19.85 |
| 328 | CD27/TGFBR2 ratio | GCST90313776 | 19.83 |
| 329 | IFNG levels | GCST90469515 | 19.76 |
| 330 | BOC levels | GCST90468458 | 19.71 |
| 331 | Dermatitis | FING00000401 | 19.70 |
| 332 | ENO2/RWDD1 ratio | GCST90314667 | 19.67 |
| 333 | MZB1/TNFRSF13B ratio | GCST90315509 | 19.65 |
| 334 | Skin cancer | GCST90475575 | 19.55 |
| 335 | AHSP/HMBS ratio | GCST90313217 | 19.48 |
| 336 | Acute pancreatitis | FING00000027 | 19.45 |
| 337 | Malignant neoplasm of thyroid gland, excluding all cancers (controls excluding all cancers) | FING00000777 | 19.41 |
| 338 | ERBIN/LYN ratio | GCST90314694 | 19.37 |
| 339 | Primary biliary cholangitis | GCST003129 | 19.36 |
| 340 | TNFRSF11A levels | GCST90277644 | 19.23 |
| 341 | FOXO3 levels | GCST90469266 | 19.23 |
| 342 | Medication use (drugs affecting bone structure and mineralization) | GCST90018773 | 19.21 |
| 343 | Mouth/teeth dental problems - None of the above | Mouth | UKBB00000489 | 19.21 |
| 344 | Lung cancer | GCST90018655 | 19.21 |
| 345 | CRTAM/ICAM3 ratio | GCST90314276 | 19.16 |
| 346 | Early-onset myasthenia gravis | GCST90093465 | 19.12 |
| 347 | Blood cell traits latent factor 20 (red cell) | GCST90559262 | 19.10 |
| 348 | Autoimmune hyperthyroidism | FING00000134 | 19.05 |
| 349 | T1 FreeSurfer DK rh supramarginal volume | GCST90385787 | 19.05 |
| 350 | DNAJB2 levels | GCST90469013 | 19.03 |
| 351 | Age hay fever, rhinitis or eczema diagnosed | Medical conditions | UKBB00000015 | 18.97 |
| 352 | CD8 on Effector Memory CD8+ T cell | GCST90002056 | 18.94 |
| 353 | GZMA/LTA ratio | GCST90315012 | 18.94 |
| 354 | Ulcerative colitis | GCST90475322 | 18.93 |
| 355 | Doctor diagnosed hayfever or allergic rhinitis | Medical information | UKBB00000192 | 18.92 |
| 356 | CCR2 on CD14+ CD16- monocyte | GCST90002004 | 18.91 |
| 357 | SRP14 levels | GCST90470742 | 18.91 |
| 358 | LBR/LGALS8 ratio | GCST90315294 | 18.91 |
| 359 | Non-allergic asthma (mode) (more control exclusions) | FING00000869 | 18.89 |
| 360 | Papillary adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers) | FING00001143 | 18.89 |
| 361 | STX6 levels | GCST90470774 | 18.88 |
| 362 | SMNDC1 levels | GCST90470681 | 18.87 |
| 363 | MSRA/PRDX5 ratio | GCST90315497 | 18.86 |
| 364 | BCL2 levels | GCST90468433 | 18.83 |
| 365 | BOLA2 or BOLA2B levels | GCST90468460 | 18.78 |
| 366 | ICD10 O60: Preterm labor and delivery | GCST90454242 | 18.74 |
| 367 | Crohn's disease NAS | FING00000367 | 18.68 |
| 368 | Diseases of white blood cells (PheCode 288) | GCST90475812 | 18.67 |
| 369 | MPHOSPH8/USP8 ratio | GCST90315479 | 18.63 |
| 370 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475444 | 18.56 |
| 371 | PM: initial answer - Orange circle| Prospective memory | UKBB00000652 | 18.55 |
| 372 | LTA4H levels | GCST90469812 | 18.52 |
| 373 | Chronic hepatitis B infection | GCST90018584 | 18.49 |
| 374 | Attendance/disability/mobility allowance - None of the above | Other sociodemographic factors | UKBB00000059 | 18.46 |
| 375 | Eosinophil count | GCST90025987 | 18.40 |
| 376 | Hyperthyroidism | GCST90319319 | 18.39 |
| 377 | Vitamin B12 deficiency anaemia | FING00001441 | 18.39 |
| 378 | Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80) | GCST90668524 | 18.38 |
| 379 | IDP T1 FIRST left hippocampus volume | GCST90002444 | 18.33 |
| 380 | Lymphocyte percentage | Blood count | UKBB00000412 | 18.33 |
| 381 | Lichen simplex chronicus and prurigo | FING00000725 | 18.30 |
| 382 | Internal derangement of knee (PheCode 835) | GCST90476282 | 18.27 |
| 383 | Principal component-derived dietary pattern 9 | GCST90133014 | 18.18 |
| 384 | Multiple myeloma or monoclonal gammopathy of undetermined significance | GCST90624746 | 18.17 |
| 385 | FOXO3/SH2B3 ratio | GCST90314881 | 18.17 |
| 386 | Crohns disease | GCST90468121 | 18.12 |
| 387 | GBP1 levels | GCST90469311 | 18.09 |
| 388 | Cervical cancer | GCST90011816 | 18.07 |
| 389 | Rheumatoid arthritis | GCST000679 | 18.06 |
| 390 | Lichen ruber planus, wide definition including periferal and oral lichen planus | FING00000722 | 17.93 |
| 391 | TALDO1 levels | GCST90470802 | 17.92 |
| 392 | APBB1IP/POLR2F ratio | GCST90313300 | 17.87 |
| 393 | FCRL6/GZMA ratio | GCST90314806 | 17.82 |
| 394 | IFI30 levels | GCST90469509 | 17.82 |
| 395 | GZMH/KLRD1 ratio | GCST90315016 | 17.68 |
| 396 | Basal cell carcinoma (PheCode 172.21) | GCST90475582 | 17.64 |
| 397 | SPINK2 levels | GCST90470722 | 17.64 |
| 398 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 17.62 |
| 399 | CRTAM/TNFRSF9 ratio | GCST90314280 | 17.60 |
| 400 | CD27/NBL1 ratio | GCST90313774 | 17.56 |
| 401 | CD244 levels | GCST90468611 | 17.52 |
| 402 | ALB/Globulin ratio | UKBB00000020 | 17.30 |
| 403 | Graves' disease | GCST90018627 | 17.26 |
| 404 | CD300A levels | GCST90468619 | 17.18 |
| 405 | Chromatiales abundance in stool | GCST90032318 | 17.13 |
| 406 | Lymphocyte percentage of white cells | GCST90002389 | 17.08 |
| 407 | Volume of right central nucleus | GCST90474916 | 17.04 |
| 408 | Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41) | GCST90668485 | 17.01 |
| 409 | PDCD1/TNFRSF4 ratio | GCST90315609 | 16.97 |
| 410 | Paraproteinemia (PheCode 270.32) | GCST90475710 | 16.95 |
| 411 | EZR levels | GCST90469162 | 16.90 |
| 412 | Frequency of stair climbing in last 4 weeks | Physical activity | UKBB00000266 | 16.88 |
| 413 | GFRA2 levels | GCST90469329 | 16.87 |
| 414 | FCRL5/TNFRSF13B ratio | GCST90314805 | 16.84 |
| 415 | Basal cell carcinoma | GCST90013410 | 16.84 |
| 416 | Nasal polyps | GCST90468143 | 16.79 |
| 417 | Prescriptions - albuterol | beta2-agonist,bronchodilator,asthma | UKBB00000658 | 16.79 |
| 418 | Prescriptions - beta2-agonist|bronchodilator|asthma | UKBB00000670 | 16.79 |
| 419 | Coeliac disease | FING00000312 | 16.78 |
| 420 | DNMBP/WWP2 ratio | GCST90314522 | 16.76 |
| 421 | KCTD5 levels | GCST90469670 | 16.75 |
| 422 | Idiopathic pulmonary fibrosis | FING00000659 | 16.74 |
| 423 | CCL17/CD69 ratio | GCST90313684 | 16.70 |
| 424 | CD7 levels | GCST90468649 | 16.70 |
| 425 | Other non-epithelial cancer of skin (PheCode 172.2) | GCST90475580 | 16.66 |
| 426 | Handedness (chirality/laterality) - Left-handed | Early life factors | UKBB00000302 | 16.66 |
| 427 | Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary Administration | UKBB00000837 | 16.65 |
| 428 | SLITRK2 levels | GCST90470670 | 16.58 |
| 429 | CCL8 levels | GCST90422346 | 16.57 |
| 430 | Preterm labour and delivery | FING00001209 | 16.55 |
| 431 | Other specified disorders of external ear | FING00001104 | 16.52 |
| 432 | Mean corpuscular hemoglobin concentration | GCST90018745 | 16.51 |
| 433 | RIDA levels | GCST90470469 | 16.45 |
| 434 | MAN2B2 levels | GCST90469844 | 16.42 |
| 435 | IDP dMRI ProbtrackX L1 str l | GCST90004269 | 16.34 |
| 436 | Urine N-acetylglutamate levels in chronic kidney disease | GCST90265569 | 16.31 |
| 437 | Cerebrospinal fluid methylmalonate (MMA) levels | GCST90318243 | 16.29 |
| 438 | Lymphoid neoplasms (P-cell phenocluster) | GCST90624737 | 16.29 |
| 439 | Primary sclerosing cholangitis | GCST004030 | 16.20 |
| 440 | HSPA1A levels | GCST90469487 | 16.20 |
| 441 | HEXIM1/TRIAP1 ratio | GCST90315054 | 16.06 |
| 442 | Crohn's disease | GCST90446793 | 16.00 |
| 443 | Rheumatoid arthritis | musculoskeletal | UKBB00000757 | 15.98 |
| 444 | Rhodanobacter abundance in stool | GCST90032536 | 15.98 |
| 445 | Lumbar disc prolapse | FING00000735 | 15.96 |
| 446 | Pollinosis | GCST90018683 | 15.94 |
| 447 | STIP1 levels | GCST90470764 | 15.94 |
| 448 | DTI TBSS MD Posterior limb of internal capsule L | GCST90384591 | 15.90 |
| 449 | Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35) | GCST90309369 | 15.89 |
| 450 | DTI TBSS MD Cingulum cingulate gyrus L | GCST90384607 | 15.88 |
| 451 | Poisoning by antibiotics | injuries & poisonings | UKBB00000653 | 15.87 |
| 452 | CCL19 levels | GCST90468571 | 15.84 |
| 453 | Blood cell traits latent factor 23 (white cell) | GCST90559265 | 15.78 |
| 454 | PTPRC levels | GCST90470380 | 15.73 |
| 455 | Cancer of urinary organs (incl. kidney and bladder) (PheCode 189) | GCST90475593 | 15.68 |
| 456 | IL5RA levels | GCST90469600 | 15.67 |
| 457 | Squamous cell carcinoma (PheCode 172.22) | GCST90475583 | 15.59 |
| 458 | DTI TBSS L1 Cingulum cingulate gyrus L | GCST90384463 | 15.58 |
| 459 | IL22 levels | GCST90469582 | 15.57 |
| 460 | Endometrial cancer | GCST006464 | 15.49 |
| 461 | TRAF3 levels | GCST90470957 | 15.48 |
| 462 | IGLC2 levels | GCST90469536 | 15.43 |
| 463 | MAVS/MED18 ratio | GCST90315389 | 15.40 |
| 464 | Rheumatoid arthritis and other inflammatory polyarthropathies | musculoskeletal | UKBB00000758 | 15.32 |
| 465 | Solitary pulmonary nodule (PheCode 514.2) | GCST90476044 | 15.31 |
| 466 | PEAR1/PECAM1 ratio | GCST90315641 | 15.29 |
| 467 | CD48 levels | GCST90468635 | 15.21 |
| 468 | Vertiginous syndromes and other disorders of vestibular system (PheCode 386) | GCST90475905 | 15.12 |
| 469 | Diseases of vocal cords and larynx+other diseases of upper respiratory tract, no elsewhere classified | FING00000432 | 15.05 |
| 470 | TIGIT levels | GCST90470865 | 15.04 |
| 471 | Nonspecific chest pain | circulatory system | UKBB00000527 | 15.03 |
| 472 | ENO3 levels | GCST90469111 | 14.99 |
| 473 | CXCL11/DKK1 ratio | GCST90314334 | 14.94 |
| 474 | CD27/NECTIN4 ratio | GCST90313775 | 14.91 |
| 475 | Plasma ascorbic acid 2-sulfate levels in chronic kidney disease | GCST90264832 | 14.90 |
| 476 | IDP dMRI TBSS L1 Posterior limb of internal capsule R | GCST90004093 | 14.88 |
| 477 | GSTA4 levels | GCST90241283 | 14.87 |
| 478 | Triacylglycerol_52:5_[M+NH4]1+ levels | GCST90060506 | 14.85 |
| 479 | Number of attempts | Prospective memory | UKBB00000531 | 14.74 |
| 480 | Melanoma | GCST90011809 | 14.74 |
| 481 | lymphocyte (fraction, maximum, inv-norm transformed) | GCST90475432 | 14.73 |
| 482 | Psoriatic arthropathies | FING00001225 | 14.72 |
| 483 | DTI autoptx MD str r tract | GCST90385244 | 14.71 |
| 484 | FCRL5/ICAM3 ratio | GCST90314802 | 14.71 |
| 485 | PSAPL1 levels | GCST90242354 | 14.70 |
| 486 | PAXX levels | GCST90470161 | 14.68 |
| 487 | Sporadic miscarriage | GCST011888 | 14.68 |
| 488 | Mean corpuscular hemoglobin concentration | GCST90002329 | 14.65 |
| 489 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475448 | 14.54 |
| 490 | ARG1 levels | GCST90468350 | 14.54 |
| 491 | RAPGEF2 levels | GCST90470426 | 14.52 |
| 492 | CD40LG/TRAF2 ratio | GCST90313828 | 14.49 |
| 493 | SMPD3 levels | GCST90470685 | 14.46 |
| 494 | Diseases of the digestive system | FING00000429 | 14.45 |
| 495 | Myasthenia gravis | GCST90432156 | 14.45 |
| 496 | T1 FreeSurfer DKT rh supramarginal volume | GCST90384377 | 14.44 |
| 497 | Mean reticulocyte volume | Blood count | UKBB00000451 | 14.44 |
| 498 | Ankylosing spondylitis | FING00000089 | 14.43 |
| 499 | Other haemoglobinopathies | FING00001053 | 14.42 |
| 500 | TNFRSF19 levels | GCST90088947 | 14.38 |
| 501 | Ulcerative rectosigmoiditis | FING00001394 | 14.35 |
| 502 | TNFSF12 levels | GCST90274846 | 14.31 |
| 503 | Ulcerative colitis | GCST004133 | 14.31 |
| 504 | Red blood cell count | GCST90018751 | 14.29 |
| 505 | Mood swings | Mental health | UKBB00000482 | 14.27 |
| 506 | SELPLG levels | GCST90470568 | 14.26 |
| 507 | Chronic lymphocytic leukemia | GCST90624738 | 14.23 |
| 508 | Melanomas of skin, dx or hx (PheCode 172.1) | GCST90475577 | 14.22 |
| 509 | AXIN1/MAVS ratio | GCST90313414 | 14.20 |
| 510 | Allergic rhinitis | FING00000071 | 14.20 |
| 511 | AK1 levels | GCST90468269 | 14.19 |
| 512 | GZMA levels | GCST90469423 | 14.18 |
| 513 | PLXNB3/SNAP23 ratio | GCST90315693 | 14.17 |
| 514 | CEP85 levels | GCST90468716 | 14.16 |
| 515 | Crohn's disease of small intestine | FING00000369 | 14.14 |
| 516 | SH2D1A levels | GCST90470617 | 14.09 |
| 517 | CDH17/PTPRM ratio | GCST90313943 | 14.07 |
| 518 | lymphocyte (fraction, mean, inv-norm transformed) | GCST90475435 | 14.07 |
| 519 | PRG2 levels | GCST90470322 | 14.04 |
| 520 | Erythematous conditions (PheCode 695) | GCST90476177 | 13.99 |
| 521 | Prescriptions - paracetamol | antipyretic | UKBB00000696 | 13.97 |
| 522 | Prescriptions - antipyretic | UKBB00000665 | 13.97 |
| 523 | T1 FreeSurfer BA lh BA2 exvivo volume | GCST90385534 | 13.94 |
| 524 | EDAR/TACC3 ratio | GCST90314589 | 13.92 |
| 525 | Plasma taurocholenate sulfate* levels in chronic kidney disease | GCST90266040 | 13.90 |
| 526 | GRAP2/MAP4K5 ratio | GCST90314982 | 13.89 |
| 527 | Juvenile rheumatoid arthirtis | FING00000706 | 13.89 |
| 528 | PEBP1 levels | GCST90470205 | 13.89 |
| 529 | Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24) | GCST90309358 | 13.87 |
| 530 | Right-hemisphere dorsal attention network to amygdala white-matter structural connectivity | GCST90302811 | 13.87 |
| 531 | DNA methylation-estimated granulocyte proportions | GCST90014287 | 13.84 |
| 532 | Other intervertebral disc disorders | FING00001063 | 13.81 |
| 533 | FASLG levels | GCST90469191 | 13.79 |
| 534 | Acute upper respiratory infections of multiple and unspecified sites | FING00000035 | 13.78 |
| 535 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 13.75 |
| 536 | DTI TBSS MD Posterior thalamic radiation R | GCST90384600 | 13.73 |
| 537 | PM: initial answer - Blue square | Prospective memory | UKBB00000651 | 13.66 |
| 538 | Biological Sibling: Asthma | GCST90476372 | 13.63 |
| 539 | 3-methyl-2-oxobutyrate levels | GCST90199677 | 13.62 |
| 540 | Treatment/medication code - ibuprofen | Medications | UKBB00000847 | 13.61 |
| 541 | aparc-a2009s rh thickness G-oc-temp-med-Lingual | GCST90003698 | 13.59 |
| 542 | Psoriasis (vulgaris), strict definition | FING00001223 | 13.56 |
| 543 | DTI TBSS MD Superior longitudinal fasciculus R | GCST90384612 | 13.53 |
| 544 | CDA levels | GCST90468660 | 13.52 |
| 545 | LCN2/S100A12 ratio | GCST90315309 | 13.51 |
| 546 | DTI TBSS MD Superior longitudinal fasciculus L | GCST90384613 | 13.48 |
| 547 | Melanomas of skin (PheCode 172.11) | GCST90475578 | 13.48 |
| 548 | CD6/EZR ratio | GCST90313890 | 13.47 |
| 549 | Crohn's disease | GCST004132 | 13.45 |
| 550 | NELL2/SEZ6L ratio | GCST90315536 | 13.43 |
| 551 | SUMF1 levels | GCST90470783 | 13.43 |
| 552 | Ratio of bis-allylic bonds to double bonds in lipids | GCST90132744 | 13.42 |
| 553 | Asthma, unspecified (mode) | FING00000120 | 13.38 |
| 554 | Hypoplasia of dental enamel, including avohilmo | FING00000652 | 13.37 |
| 555 | Operation code - hysterectomy | Operations | UKBB00000559 | 13.37 |
| 556 | DTI TBSS L2 Posterior thalamic radiation R | GCST90384504 | 13.27 |
| 557 | MICB or MICA levels | GCST90469905 | 13.27 |
| 558 | CD74/NPDC1 ratio | GCST90313895 | 13.25 |
| 559 | CDSN/LY6D ratio | GCST90313997 | 13.25 |
| 560 | B2M levels | GCST90468409 | 13.23 |
| 561 | ITGB1BP2/TIA1 ratio | GCST90315222 | 13.22 |
| 562 | Athlete's foot (PheCode 110.12) | GCST90475563 | 13.16 |
| 563 | CEP43/MPHOSPH8 ratio | GCST90314019 | 13.16 |
| 564 | DTI autoptx MD slf r tract | GCST90385242 | 13.14 |
| 565 | Prospective memory result | Prospective memory | UKBB00000713 | 13.14 |
| 566 | Current Smoker | FING00000371 | 13.12 |
| 567 | CWC15 levels | GCST90468920 | 13.09 |
| 568 | ARHGAP25/RNF41 ratio | GCST90313345 | 13.09 |
| 569 | Vanillactate levels | GCST90199978 | 13.08 |
| 570 | BCR/FOXO1 ratio | GCST90313490 | 13.06 |
| 571 | Belief that own life is meaningful | Happiness and subjective well-being | UKBB00000090 | 13.05 |
| 572 | IPCEF1/SPARC ratio | GCST90315186 | 13.01 |
| 573 | IDP dMRI TBSS OD Posterior limb of internal capsule R | GCST90004420 | 13.01 |
| 574 | Tryptophan betaine levels | GCST90199819 | 13.01 |
| 575 | ST13 levels | GCST90470751 | 13.00 |
| 576 | CEACAM8/PGLYRP1 ratio | GCST90314003 | 12.97 |
| 577 | Symptoms involving digestive system (PheCode 561) | GCST90476069 | 12.96 |
| 578 | CC2D1A/STAMBP ratio | GCST90313664 | 12.94 |
| 579 | PRKAR1A/SNAP23 ratio | GCST90315728 | 12.94 |
| 580 | Acute bronchitis | FING00000021 | 12.91 |
| 581 | MAP2K1 levels | GCST90469851 | 12.88 |
| 582 | Avoided activities or situations because of previous stressful experience in past month | Traumatic events | UKBB00000083 | 12.85 |
| 583 | Malignant neoplasm of skin, excluding all cancers (controls excluding all cancers) | FING00000772 | 12.80 |
| 584 | Conjunctivitis | FING00000346 | 12.79 |
| 585 | Acquired hypothyroidism (PheCode 244.2) | GCST90475650 | 12.79 |
| 586 | FUT8/TNFSF14 ratio | GCST90314895 | 12.78 |
| 587 | Omega-3 fatty acid levels | GCST90502422 | 12.77 |
| 588 | LAYN/PTPRN2 ratio | GCST90315290 | 12.75 |
| 589 | BACH1/SNAP23 ratio | GCST90313446 | 12.73 |
| 590 | CCN2/DKK1 ratio | GCST90313710 | 12.72 |
| 591 | Cleft hard palate NOS | FING00000306 | 12.70 |
| 592 | NAP1L4 levels | GCST90469998 | 12.70 |
| 593 | Left-hemisphere dorsal attention network to putamen white-matter structural connectivity | GCST90302703 | 12.69 |
| 594 | ATP5IF1/LYN ratio | GCST90313389 | 12.68 |
| 595 | Regional enteritis (PheCode 555.1) | GCST90476066 | 12.67 |
| 596 | Percentage of fucosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP80) | GCST90668758 | 12.64 |
| 597 | Average total household income before tax | Household | UKBB00000081 | 12.62 |
| 598 | CRACR2A/LBR ratio | GCST90314228 | 12.56 |
| 599 | Other contact dermatitis | FING00000990 | 12.56 |
| 600 | IL15/NCR1 ratio | GCST90315150 | 12.52 |
| 601 | mean corpuscular volume (MCV, minimum, inv-norm transformed) | GCST90475474 | 12.51 |
| 602 | CCL5/TACC3 ratio | GCST90313707 | 12.51 |
| 603 | Multiple myeloma | GCST90624747 | 12.50 |
| 604 | EDAR/F2R ratio | GCST90314577 | 12.46 |
| 605 | Basophil count | GCST90002293 | 12.43 |
| 606 | DCTN1/TRIAP1 ratio | GCST90314434 | 12.41 |
| 607 | TSC1 levels | GCST90470972 | 12.40 |
| 608 | PRG3 levels | GCST90470323 | 12.37 |
| 609 | Neoplasm of uncertain behavior of skin (PheCode 173) | GCST90475585 | 12.37 |
| 610 | Polymyalgia rheumatica | FING00001188 | 12.36 |
| 611 | GIMAP7 levels | GCST90469345 | 12.34 |
| 612 | Skin cancer | GCST90475189 | 12.32 |
| 613 | Ceramide (d18:2/24:1) levels | GCST90024684 | 12.31 |
| 614 | CALCOCO1/IRAG2 ratio | GCST90313604 | 12.31 |
| 615 | General happiness | Happiness and subjective well-being | UKBB00000280 | 12.30 |
| 616 | DTI autoptx L3 ifo l tract | GCST90385205 | 12.29 |
| 617 | MAPRE3 levels | GCST90469859 | 12.29 |
| 618 | ICD10 N97.8: Female infertility of other origin | GCST90454225 | 12.27 |
| 619 | Ankylosing spondylitis, strict definition | FING00000090 | 12.24 |
| 620 | Ever Smoker | FING00000522 | 12.23 |
| 621 | Lymphoid leukemia, chronic (PheCode 204.12) | GCST90475613 | 12.18 |
| 622 | Omega-3 fatty acids to total fatty acids percentage | GCST90502087 | 12.17 |
| 623 | Mean sphered cell volume (UKB data field 30270) | GCST90468089 | 12.14 |
| 624 | Ulcerative colitis (strict definition, require KELA, min 2 HDR) | FING00001388 | 12.10 |
| 625 | Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systems | UKBB00000625 | 12.06 |
| 626 | HSPB1 levels | GCST90179317 | 12.05 |
| 627 | Ulcerative colitis | GCST90446795 | 12.04 |
| 628 | Lymphocyte percentage of white cells | GCST004632 | 12.01 |
| 629 | SUOX levels | GCST90470785 | 11.99 |
| 630 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 11.96 |
| 631 | Rosacea (PheCode 695.3) | GCST90476178 | 11.95 |
| 632 | Skin color (cheek, ITA value) | GCST90502780 | 11.93 |
| 633 | BACH1/CD2AP ratio | GCST90313435 | 11.90 |
| 634 | IPCEF1/TBCC ratio | GCST90315188 | 11.84 |
| 635 | Principal component-derived dietary pattern 26 | GCST90133031 | 11.82 |
| 636 | TNFRSF13B/TNFSF13B ratio | GCST90315933 | 11.78 |
| 637 | Acute renal failure | FING00000030 | 11.78 |
| 638 | Autoimmune hepatitis | GCST90018565 | 11.76 |
| 639 | X-11550 levels | GCST90243648 | 11.74 |
| 640 | Takes medication for Skin condition (ex. Eczema, Psoriasis)? | GCST90475275 | 11.70 |
| 641 | 5alpha-pregnan-3beta,20alpha-diol monosulfate (2) levels | GCST90199854 | 11.68 |
| 642 | DAG1/F2R ratio | GCST90314374 | 11.64 |
| 643 | ESAM/FUT8 ratio | GCST90314711 | 11.62 |
| 644 | FCRL6/KLRD1 ratio | GCST90314807 | 11.61 |
| 645 | VEGFB levels | GCST90471035 | 11.60 |
| 646 | Spondylopathies (FG) | FING00001326 | 11.60 |
| 647 | TOR1AIP1 levels | GCST90470935 | 11.59 |
| 648 | LY96 levels | GCST90469823 | 11.53 |
| 649 | Non-cancer illness code, self-reported - hiatus hernia | Medical conditions | UKBB00000515 | 11.52 |
| 650 | Fibroblastic disorders | FING00000542 | 11.52 |
| 651 | PLAUR levels | GCST90012051 | 11.52 |
| 652 | CXCL5/MESD ratio | GCST90314350 | 11.51 |
| 653 | CA1/HMBS ratio | GCST90313573 | 11.49 |
| 654 | DTI TBSS L3 Posterior thalamic radiation R | GCST90384552 | 11.43 |
| 655 | HBEGF/WWP2 ratio | GCST90315038 | 11.43 |
| 656 | CD86 levels | GCST90468654 | 11.42 |
| 657 | DTI TBSS MD External capsule L | GCST90384605 | 11.42 |
| 658 | TPSAB1 levels | GCST90470951 | 11.40 |
| 659 | Brain age gap | GCST90558034 | 11.40 |
| 660 | Actinic keratosis (PheCode 702.1) | GCST90476204 | 11.38 |
| 661 | FOXO1/NFATC1 ratio | GCST90314873 | 11.37 |
| 662 | FUT8/RSPO1 ratio | GCST90314891 | 11.36 |
| 663 | EDAR/ERBIN ratio | GCST90314575 | 11.34 |
| 664 | Thoracic or lumbosacral neuritis or radiculitis, unspecified (PheCode 763) | GCST90476268 | 11.33 |
| 665 | Types of physical activity in last 4 weeks - None of the above | Physical activity | UKBB00000872 | 11.32 |
| 666 | YOD1 levels | GCST90471090 | 11.29 |
| 667 | CRACR2A/IRAG2 ratio | GCST90314227 | 11.24 |
| 668 | mean corpuscular volume (MCV, maximum, inv-norm transformed) | GCST90475466 | 11.19 |
| 669 | Colitis, primary sclerosing, strict definition | FING00000313 | 11.19 |
| 670 | PPP1R2/TBL1X ratio | GCST90315720 | 11.18 |
| 671 | KIR3DL1 levels | GCST90469687 | 11.17 |
| 672 | ITGB7 levels | GCST90469647 | 11.15 |
| 673 | Bifidobacterium catenulatum abundance in stool | GCST90032224 | 11.12 |
| 674 | EDAR/EGF ratio | GCST90314573 | 11.11 |
| 675 | Other and unspecified tonsillitis | FING00000954 | 11.11 |
| 676 | DTI autoptx L1 cst r tract | GCST90385148 | 11.10 |
| 677 | IDP dMRI ProbtrackX L1 ifo r | GCST90004259 | 11.08 |
| 678 | EDAR/LAT2 ratio | GCST90314582 | 11.08 |
| 679 | Degenerative skin conditions and other dermatoses (PheCode 702) | GCST90476202 | 11.06 |
| 680 | Eosinophil percentage of white cells variance | GCST90565690 | 11.06 |
| 681 | aparc-a2009s rh volume S-collat-transv-ant | GCST90003048 | 11.05 |
| 682 | Other systemic involvement of connective tissue (FG) | FING00001116 | 11.01 |
| 683 | Urticaria | FING00001408 | 11.00 |
| 684 | Number of days/week walked 10+ minutes | Physical activity | UKBB00000535 | 10.99 |
| 685 | ADA levels | GCST90468231 | 10.96 |
| 686 | PRKAB1 levels | GCST90470324 | 10.95 |
| 687 | GBP4 levels | GCST90469313 | 10.94 |
| 688 | IDP dMRI TBSS ISOVF Genu of corpus callosum | GCST90004479 | 10.93 |
| 689 | ENO2/PLXNA4 ratio | GCST90314665 | 10.91 |
| 690 | CD69/EDAR ratio | GCST90313875 | 10.90 |
| 691 | Pilonidal cyst | FING00001167 | 10.88 |
| 692 | APRT/CD63 ratio | GCST90313334 | 10.84 |
| 693 | BCR/ITGB1BP2 ratio | GCST90313494 | 10.84 |
| 694 | Prescriptions - antispasmodic | UKBB00000666 | 10.83 |
| 695 | Atopic dermatitis | GCST90018564 | 10.83 |
| 696 | DTI TBSS MD Superior corona radiata R | GCST90384596 | 10.81 |
| 697 | aparc-Desikan rh volume insula | GCST90002834 | 10.79 |
| 698 | T1 FreeSurfer aseg Right-Pallidum | GCST90384164 | 10.76 |
| 699 | WARS levels | GCST90471066 | 10.75 |
| 700 | Long-standing illness, disability or infirmity | General health | UKBB00000409 | 10.74 |
| 701 | Mean reticulocyte volume | GCST90025975 | 10.74 |
| 702 | DTI autoptx L1 cst l tract | GCST90385147 | 10.73 |
| 703 | DBNL/EDAR ratio | GCST90314416 | 10.69 |
| 704 | CD27/TNFRSF9 ratio | GCST90313778 | 10.64 |
| 705 | Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditions | UKBB00000369 | 10.62 |
| 706 | Dermatomycosis (PheCode 110.2) | GCST90475565 | 10.61 |
| 707 | PPM1B levels | GCST90470296 | 10.58 |
| 708 | N-acetylmethionine levels | GCST90200289 | 10.55 |
| 709 | T1 FreeSurfer a2009s lh S postcentral area | GCST90384734 | 10.55 |
| 710 | Volume of right cortical nucleus | GCST90475033 | 10.54 |
| 711 | CDH17/PECAM1 ratio | GCST90313942 | 10.54 |
| 712 | DTI autoptx L3 ilf l tract | GCST90385207 | 10.53 |
| 713 | Basal cell carcinoma, including avohilmo, excluding all cancers (controls excluding all cancers) | FING00000143 | 10.52 |
| 714 | CDKN2D/FOXO1 ratio | GCST90313985 | 10.51 |
| 715 | Hair colour (natural, before greying): Red (UKB data field 1747_2) | GCST90041837 | 10.50 |
| 716 | Atrial septal defect | FING00000128 | 10.49 |
| 717 | Mean reticulocyte volume (UKB data field 30260) | GCST90468088 | 10.48 |
| 718 | Mean reticulocyte volume | GCST90002396 | 10.47 |
| 719 | Bronchitis | FING00000228 | 10.46 |
| 720 | Taking other prescription medications | Medication | UKBB00000813 | 10.45 |
| 721 | ITGB2 levels | GCST90469644 | 10.45 |
| 722 | CXCL16 levels | GCST90240524 | 10.44 |
| 723 | TXNDC15 levels | GCST90470990 | 10.42 |
| 724 | Cervicalgia (PheCode 761) | GCST90476267 | 10.42 |
| 725 | Avocado liking | GCST90094694 | 10.42 |
| 726 | T1 CAT volume R RightThalamus | GCST90384097 | 10.42 |
| 727 | Triacylglycerol_56:6_[M+NH4]1+ levels | GCST90060553 | 10.41 |
| 728 | Ulcerative colitis | GCST90468152 | 10.39 |
| 729 | LCN2/PGLYRP1 ratio | GCST90315306 | 10.37 |
| 730 | AHCY/HSPA1A ratio | GCST90313211 | 10.35 |
| 731 | Mean sphered cell volume | Blood count | UKBB00000452 | 10.34 |
| 732 | Educational attainment | GCST002598 | 10.33 |
| 733 | SNAP23/TXLNA ratio | GCST90315857 | 10.31 |
| 734 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502074 | 10.30 |
| 735 | Biological Mother: High blood pressure | GCST90475490 | 10.29 |
| 736 | Basal cell carcinoma, excluding all cancers (controls excluding all cancers) | FING00000142 | 10.28 |
| 737 | Late-onset myasthenia gravis | GCST90093466 | 10.27 |
| 738 | THBS2 levels | GCST90470854 | 10.22 |
| 739 | Methods of admission to hospital (recoded) - Elective admission: Booked | Summary Administration | UKBB00000461 | 10.21 |
| 740 | LRRC37A2 levels | GCST90469802 | 10.21 |
| 741 | ELOA levels | GCST90469104 | 10.20 |
| 742 | CDH17/SPINT1 ratio | GCST90313944 | 10.16 |
| 743 | Ectopic pregnancy | FING00000487 | 10.16 |
| 744 | Pollen allergy | FING00001176 | 10.16 |
| 745 | CD27 levels | GCST90468615 | 10.14 |
| 746 | Prostate cancer | GCST90018685 | 10.14 |
| 747 | Suppurative and unspecified otitis media | FING00001346 | 10.13 |
| 748 | INSR levels | GCST90469623 | 10.11 |
| 749 | Triacylglycerol_52:4_[M+NH4]1+ levels | GCST90060508 | 10.11 |
| 750 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 101) | GCST90320920 | 10.08 |
| 751 | PBLD levels | GCST90470163 | 10.06 |
| 752 | Other dorsopathies, not elsewhere classified | FING00001041 | 10.03 |
| 753 | HEXIM1/TBL1X ratio | GCST90315053 | 10.03 |
| 754 | BTN3A2 levels | GCST90468481 | 10.02 |
| 755 | Red blood cell count | GCST90002364 | 10.01 |
| 756 | DTI TBSS L3 Posterior thalamic radiation L | GCST90384553 | 9.98 |
| 757 | DTI autoptx L3 slf r tract | GCST90385215 | 9.97 |
| 758 | Type 1 diabetes with ophthalmic manifestations (PheCode 250.13) | GCST90475663 | 9.97 |
| 759 | IDP T1 FAST ROIs R front operc cortex | GCST90002532 | 9.96 |
| 760 | CD27/TNFRSF13B ratio | GCST90313777 | 9.95 |
| 761 | IL2RA levels | GCST90469585 | 9.95 |
| 762 | Overweight, obesity and other hyperalimentation (PheCode 278) | GCST90475759 | 9.95 |
| 763 | CANT1/ROR1 ratio | GCST90313620 | 9.93 |
| 764 | Dissection of aorta | FING00000467 | 9.88 |
| 765 | Irritable bowel syndrome | FING00000702 | 9.86 |
| 766 | DAB2/FKBP1B ratio | GCST90314362 | 9.84 |
| 767 | POF1B levels | GCST90470281 | 9.84 |
| 768 | Back pain (PheCode 760) | GCST90476266 | 9.82 |
| 769 | Psoriatic arthritis vs Cutaneous psoriasis | GCST90243957 | 9.82 |
| 770 | CIAPIN1/SNX9 ratio | GCST90314068 | 9.81 |
| 771 | Cataracts | GCST90018594 | 9.80 |
| 772 | SNAP29/VEGFC ratio | GCST90315862 | 9.76 |
| 773 | Skin cancer | neoplasms | UKBB00000772 | 9.75 |
| 774 | CA3/HMBS ratio | GCST90313584 | 9.73 |
| 775 | AHSP/BLVRB ratio | GCST90313214 | 9.71 |
| 776 | FOXO1/MAP4K5 ratio | GCST90314872 | 9.70 |
| 777 | APEX1 levels | GCST90468329 | 9.69 |
| 778 | DTI TBSS MD Cingulum cingulate gyrus R | GCST90384606 | 9.69 |
| 779 | CD20 on IgD- CD27- B cell | GCST90001754 | 9.69 |
| 780 | GMPR2 levels | GCST90469367 | 9.68 |
| 781 | IDP dMRI TBSS FA Fornix | GCST90003882 | 9.65 |
| 782 | Alcohol-induced chronic pancreatitis | FING00000055 | 9.61 |
| 783 | TP53BP1 levels | GCST90470936 | 9.60 |
| 784 | FOLR2/HAVCR2 ratio | GCST90314865 | 9.59 |
| 785 | NFATC3 levels | GCST90470034 | 9.59 |
| 786 | DOK2/PDLIM7 ratio | GCST90314535 | 9.58 |
| 787 | DTI TBSS FA Posterior thalamic radiation R | GCST90384408 | 9.57 |
| 788 | Uterine fibroids | GCST90461958 | 9.54 |
| 789 | TNF/TNFRSF1B ratio | GCST90315942 | 9.53 |
| 790 | RAP1A levels | GCST90470425 | 9.53 |
| 791 | CD27/CD79B ratio | GCST90313770 | 9.53 |
| 792 | DAPP1/ITGB1BP2 ratio | GCST90314388 | 9.51 |
| 793 | White blood cell count | GCST90025985 | 9.49 |
| 794 | APRT/MIF ratio | GCST90313336 | 9.48 |
| 795 | mean corpuscular hemoglobin concentration (MCHC, mean, inv-norm transformed) | GCST90475456 | 9.47 |
| 796 | Strenuous sports or other exercises | GCST006100 | 9.46 |
| 797 | CD58/MEGF10 ratio | GCST90313853 | 9.45 |
| 798 | F2R/TNFRSF14 ratio | GCST90314739 | 9.44 |
| 799 | C1R levels | GCST90468493 | 9.42 |
| 800 | TNFSF13B levels | GCST90470920 | 9.41 |
| 801 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475450 | 9.41 |
| 802 | T1 FreeSurfer BA lh V2 exvivo thickness | GCST90385529 | 9.40 |
| 803 | IDP dMRI TBSS L1 Posterior limb of internal capsule L | GCST90004094 | 9.39 |
| 804 | Bread type: Wholemeal/wholegrain vs white and brown (UKB data field 1448) | GCST90132968 | 9.38 |
| 805 | EBAG9/TGFB1 ratio | GCST90314570 | 9.37 |
| 806 | AXL/IL18BP ratio | GCST90313420 | 9.35 |
| 807 | DTI TBSS L3 Genu of corpus callosum | GCST90384526 | 9.34 |
| 808 | Rheumatoid arthritis (PheCode 714.1) | GCST90476230 | 9.34 |
| 809 | Scar conditions and fibrosis of skin (PheCode 701.2) | GCST90476198 | 9.33 |
| 810 | EFNA4/TNFRSF9 ratio | GCST90314606 | 9.32 |
| 811 | Volume of left anterior amygdaloid area | GCST90474937 | 9.32 |
| 812 | Hernia abdominopelvic cavity | GCST90086087 | 9.32 |
| 813 | HEPH levels | GCST90469446 | 9.32 |
| 814 | Telomere length (principal component 1) | GCST90435144 | 9.30 |
| 815 | aparc-a2009s rh area S-collat-transv-ant | GCST90003420 | 9.30 |
| 816 | Fluid intelligence score decline (difference score) | GCST90565862 | 9.29 |
| 817 | FCRL5 levels | GCST90469208 | 9.27 |
| 818 | Renal tubulo-interstitial diseases | FING00001251 | 9.27 |
| 819 | CD46/TIMP1 ratio | GCST90313837 | 9.26 |
| 820 | Mean corpuscular volume | GCST90002392 | 9.22 |
| 821 | AHNAK levels | GCST90468261 | 9.21 |
| 822 | FOXO1/USP8 ratio | GCST90314879 | 9.19 |
| 823 | IDP dMRI TBSS OD Posterior limb of internal capsule L | GCST90004421 | 9.17 |
| 824 | CD84/F2R ratio | GCST90313912 | 9.13 |
| 825 | wg lh intensity-contrast rostralmiddlefrontal | GCST90003818 | 9.12 |
| 826 | DTI autoptx L2 slf l tract | GCST90385187 | 9.12 |
| 827 | Allergic conjunctivitis | FING00000067 | 9.10 |
| 828 | MED18/TACC3 ratio | GCST90315414 | 9.09 |
| 829 | IL10 levels | GCST90469546 | 9.09 |
| 830 | Number of days/week of vigorous physical activity 10+ minutes | Physical activity | UKBB00000534 | 9.07 |
| 831 | Dried fruit consumption | GCST90132980 | 9.03 |
| 832 | Urine GlcNAc sulfate conjugate of C21H34O2 steroid** levels in chronic kidney disease | GCST90265175 | 9.01 |
| 833 | Attendance/disability/mobility allowance - Disability living allowance | Other sociodemographic factors | UKBB00000058 | 9.00 |
| 834 | mean corpuscular hemoglobin (MCH, mean, inv-norm transformed) | GCST90475446 | 8.99 |
| 835 | TP53I3 levels | GCST90470937 | 8.98 |
| 836 | CLEC4D/CLEC6A ratio | GCST90314109 | 8.97 |
| 837 | CDKN2D/TACC3 ratio | GCST90313992 | 8.97 |
| 838 | KIFBP/LYN ratio | GCST90315246 | 8.96 |
| 839 | Mean spheric corpuscular volume | GCST90002397 | 8.95 |
| 840 | Diseases of esophagus (PheCode 530) | GCST90476045 | 8.92 |
| 841 | CXCL5/PLXNA4 ratio | GCST90314351 | 8.92 |
| 842 | PGR levels | GCST90470223 | 8.89 |
| 843 | DTI TBSS MD Posterior corona radiata L | GCST90384599 | 8.89 |
| 844 | VSTM2B levels | GCST90471056 | 8.88 |
| 845 | mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed) | GCST90475442 | 8.88 |
| 846 | HTRA2/SIAE ratio | GCST90315097 | 8.85 |
| 847 | Spondylosis and allied disorders (PheCode 721) | GCST90476235 | 8.82 |
| 848 | F5 levels | GCST90446466 | 8.81 |
| 849 | MED18/TBL1X ratio | GCST90315415 | 8.81 |
| 850 | DTI TBSS L2 Genu of corpus callosum | GCST90384478 | 8.80 |
| 851 | Spondylosis without myelopathy (PheCode 721.1) | GCST90476236 | 8.77 |
| 852 | Other non-epithelial cancer of skin | neoplasms | UKBB00000615 | 8.77 |
| 853 | IL32 levels | GCST90469591 | 8.77 |
| 854 | Disorders of plasma protein metabolism (PheCode 270.3) | GCST90475709 | 8.74 |
| 855 | Mean corpuscular hemoglobin | GCST90002390 | 8.73 |
| 856 | IGBP1 levels | GCST90469521 | 8.72 |
| 857 | Pain (PheCode 338) | GCST90475836 | 8.72 |
| 858 | BAG6/BMP6 ratio | GCST90313450 | 8.70 |
| 859 | T1 CAT volume L VIIIa | GCST90384127 | 8.69 |
| 860 | rfMRI connectivity (ICA100 edge 912) | GCST90005765 | 8.68 |
| 861 | NT5C levels | GCST90470092 | 8.68 |
| 862 | CDSN/WFDC12 ratio | GCST90313999 | 8.68 |
| 863 | EDAR/SNAP23 ratio | GCST90314587 | 8.67 |
| 864 | FKBP4 levels | GCST90469243 | 8.66 |
| 865 | Linoleic acid levels | GCST90502009 | 8.66 |
| 866 | SNAP23/TBL1X ratio | GCST90315856 | 8.65 |
| 867 | MVK/SERPINE1 ratio | GCST90315505 | 8.65 |
| 868 | Plasma N-acetyltaurine levels in chronic kidney disease | GCST90265600 | 8.64 |
| 869 | CAPG levels | GCST90468537 | 8.63 |
| 870 | Phenylacetate levels | GCST90199630 | 8.62 |
| 871 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 8.62 |
| 872 | SNX15 levels | GCST90470699 | 8.62 |
| 873 | Intrinsic epigenetic age acceleration | GCST90014290 | 8.61 |
| 874 | Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS), excluding all cancers (controls excluding all cancers) | FING00000846 | 8.61 |
| 875 | DIABLO/GRAP2 ratio | GCST90314466 | 8.60 |
| 876 | Snoring | Sleep | UKBB00000784 | 8.60 |
| 877 | Ulcerative enterocolitis | FING00001391 | 8.59 |
| 878 | S100A12 levels | GCST90470513 | 8.58 |
| 879 | Urine 5-acetylamino-6-amino-3-methyluracil levels in chronic kidney disease | GCST90264674 | 8.58 |
| 880 | TACC3/TBC1D23 ratio | GCST90315900 | 8.56 |
| 881 | FUT8/TNFSF12 ratio | GCST90314894 | 8.56 |
| 882 | Citrulline levels | GCST90200403 | 8.55 |
| 883 | CDC27 levels | GCST90468664 | 8.55 |
| 884 | Cancer of bronchus; lung (PheCode 165.1) | GCST90475573 | 8.54 |
| 885 | ZNF830 levels | GCST90471102 | 8.54 |
| 886 | CALCOCO1/TBC1D5 ratio | GCST90313610 | 8.54 |
| 887 | Hair colour (natural, before greying) - Dark brown | Sun exposure | UKBB00000297 | 8.54 |
| 888 | CTSC/PLA2G15 ratio | GCST90314311 | 8.53 |
| 889 | Volume of left central nucleus | GCST90474883 | 8.51 |
| 890 | HippSubfield lh volume Whole-hippocampal-head | GCST90002688 | 8.50 |
| 891 | Takes medication for asthma? | GCST90475260 | 8.50 |
| 892 | UBXN1 levels | GCST90471004 | 8.45 |
| 893 | Percentage of fucosylation of monogalactosylated structures in total neutral plasma glycans (GP74) | GCST90668518 | 8.45 |
| 894 | LPCAT2/SERPINB8 ratio | GCST90315328 | 8.45 |
| 895 | GDNF levels | GCST90274792 | 8.43 |
| 896 | ECM1 levels | GCST90469065 | 8.40 |
| 897 | HLA-A levels | GCST90469457 | 8.39 |
| 898 | Atrophic disorders of skin | FING00000129 | 8.39 |
| 899 | Dorsopathies | FING00000473 | 8.38 |
| 900 | IDP dMRI TBSS L1 Retrolenticular part of internal capsule R | GCST90004095 | 8.36 |
| 901 | JCHAIN levels | GCST90469661 | 8.35 |
| 902 | CRTAM/KLRD1 ratio | GCST90314277 | 8.35 |
| 903 | Percentage of fucosylation of monogalactosylated structures (with bisecting GlcNAc) in total neutral plasma glycans (GP82) | GCST90668526 | 8.35 |
| 904 | IDP dMRI TBSS OD Superior fronto-occipital fasciculus R | GCST90004444 | 8.34 |
| 905 | Thyroid cancer (PheCode 193) | GCST90475600 | 8.34 |
| 906 | Neutrophill percentage | Blood count | UKBB00000498 | 8.34 |
| 907 | DNAJC9 levels | GCST90469018 | 8.33 |
| 908 | FUT8/VEGFC ratio | GCST90314896 | 8.32 |
| 909 | Bread type - Wholemeal or wholegrain | Diet | UKBB00000107 | 8.31 |
| 910 | Father's age | Family history | UKBB00000240 | 8.30 |
| 911 | CLEC1B/DAB2 ratio | GCST90314086 | 8.30 |
| 912 | Other malignant neoplasms of skin | Melanoma and other malignant neoplasms of skin | UKBB00000613 | 8.30 |
| 913 | N-acetyl-2-aminoadipate levels | GCST90200268 | 8.29 |
| 914 | IGSF8/NECTIN2 ratio | GCST90315140 | 8.29 |
| 915 | Other malignant neoplasms of skin (=non-melanoma skin cancer), excluding all cancers (controls excluding all cancers) | FING00001067 | 8.29 |
| 916 | Polyp of the female genital tract | FING00001190 | 8.29 |
| 917 | PSIP1 levels | GCST90470354 | 8.28 |
| 918 | DTYMK levels | GCST90469049 | 8.27 |
| 919 | TLR4 levels | GCST90470880 | 8.22 |
| 920 | Oxalate (ethanedioate) levels | GCST90199672 | 8.21 |
| 921 | MAP2K6/TBL1X ratio | GCST90315378 | 8.20 |
| 922 | CXCL5/PPIB ratio | GCST90314352 | 8.20 |
| 923 | Methionine sulfone levels | GCST90199961 | 8.19 |
| 924 | Other arthritis (FG) | FING00000964 | 8.18 |
| 925 | Carboplatin drug response (IC50) | GCST90011783 | 8.18 |
| 926 | PARP1 levels | GCST90470160 | 8.17 |
| 927 | Malignant neoplasm, excluding all cancers (controls excluding all cancers) | FING00000780 | 8.16 |
| 928 | Neutrophill percentage (UKB data field 30200) | GCST90468093 | 8.16 |
| 929 | Epstein-Barr virus ZEBRA antibody levels | GCST90006901 | 8.15 |
| 930 | Hair colour (natural, before greying): Dark brown (UKB data field 1747_4) | GCST90041839 | 8.14 |
| 931 | Neutrophil percentage of white cells | GCST90002399 | 8.13 |
| 932 | Happiness | Mental health | UKBB00000305 | 8.12 |
| 933 | Human herpes virus 7 U14 antibody levels | GCST90006909 | 8.08 |
| 934 | Bell's palsy | FING00000144 | 8.07 |
| 935 | RBP5 levels | GCST90470439 | 8.07 |
| 936 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 57) | GCST90320876 | 8.06 |
| 937 | Non-cancer illness year/age first occurred | Medical conditions | UKBB00000523 | 8.04 |
| 938 | DTI autoptx MD fma tract | GCST90385230 | 8.04 |
| 939 | T1 CAT volume R RightPutamen | GCST90384101 | 8.04 |
| 940 | Handedness (chirality/laterality) - Right-handed | Early life factors | UKBB00000303 | 8.03 |
| 941 | Beta-hydroxyisovaleroylcarnitine levels | GCST90199802 | 8.02 |
| 942 | HBEGF/PLXNA4 ratio | GCST90315036 | 8.02 |
| 943 | UROD levels | GCST90471016 | 8.01 |
| 944 | IPCEF1/SMAD1 ratio | GCST90315185 | 8.00 |
| 945 | CNTNAP2/DPP6 ratio | GCST90314168 | 7.95 |
| 946 | NELL1 levels | GCST90242481 | 7.95 |
| 947 | CD163/ICAM1 ratio | GCST90313735 | 7.95 |
| 948 | Triacylglycerol_56:5_[M+NH4]1+ levels | GCST90060554 | 7.92 |
| 949 | Other cancer | GCST90475181 | 7.89 |
| 950 | Malignant neoplasm of lip, excluding all cancers (controls excluding all cancers) | FING00000764 | 7.87 |
| 951 | Crohn's disease | GCST90475318 | 7.87 |
| 952 | MICB_MICA/TEK ratio | GCST90315446 | 7.86 |
| 953 | APBB1IP levels | GCST90468327 | 7.85 |
| 954 | NINJ1 levels | GCST90470049 | 7.85 |
| 955 | Mean corpuscular haemoglobin (UKB data field 30050) | GCST90468084 | 7.84 |
| 956 | Body fat rate | GCST90278619 | 7.83 |
| 957 | GAPDH levels | GCST90469302 | 7.83 |
| 958 | Asthma | GCST90086047 | 7.81 |
| 959 | EBAG9/TBCC ratio | GCST90314568 | 7.79 |
| 960 | Principal component-derived dietary pattern 12 | GCST90133017 | 7.78 |
| 961 | How are people in household related to participant - Husband, wife or partner | Household | UKBB00000330 | 7.78 |
| 962 | TBCA levels | GCST90470812 | 7.77 |
| 963 | GPI levels | GCST90469391 | 7.74 |
| 964 | Chronic diseases of tonsils and adenoids | FING00000283 | 7.73 |
| 965 | NFATC1/SPRY2 ratio | GCST90315539 | 7.72 |
| 966 | CXCL17/LAMP3 ratio | GCST90314340 | 7.71 |
| 967 | DTI TBSS L3 Superior corona radiata L | GCST90384549 | 7.71 |
| 968 | TIA1/USP8 ratio | GCST90315920 | 7.68 |
| 969 | mean corpuscular hemoglobin concentration (MCHC, maximum, inv-norm transformed) | GCST90475452 | 7.67 |
| 970 | Number of puzzles correctly solved (baseline) | GCST90565840 | 7.65 |
| 971 | AXIN1/ITGB1BP2 ratio | GCST90313412 | 7.63 |
| 972 | Dissociative [conversion] disorders | FING00000468 | 7.63 |
| 973 | ICAM4 levels | GCST90469501 | 7.63 |
| 974 | Active to sedentary transition probability | GCST90061429 | 7.61 |
| 975 | DAG1/DBNL ratio | GCST90314372 | 7.60 |
| 976 | FOXO1/IRAK4 ratio | GCST90314870 | 7.59 |
| 977 | Actinic keratosis | FING00000013 | 7.58 |
| 978 | CASP10/ING1 ratio | GCST90313625 | 7.58 |
| 979 | IRAK1/SPRY2 ratio | GCST90315196 | 7.56 |
| 980 | NECTIN2/NPDC1 ratio | GCST90315528 | 7.56 |
| 981 | FUT3 or FUT5 levels | GCST90469280 | 7.56 |
| 982 | N-formylmethionine levels | GCST90200343 | 7.56 |
| 983 | SLAMF1 levels | GCST90470649 | 7.55 |
| 984 | DNAJB14 levels | GCST90427235 | 7.55 |
| 985 | CD69/NFATC1 ratio | GCST90313879 | 7.54 |
| 986 | Dried fruit liking | GCST90094756 | 7.52 |
| 987 | aseg lh volume Accumbens-area | GCST90002626 | 7.52 |
| 988 | Basophil count | GCST90018726 | 7.51 |
| 989 | CCN2/TACC3 ratio | GCST90313717 | 7.50 |
| 990 | SPESP1 levels | GCST90470720 | 7.49 |
| 991 | LBR/POLR2F ratio | GCST90315297 | 7.48 |
| 992 | ESAM/TNFRSF14 ratio | GCST90314720 | 7.47 |
| 993 | Suffer from 'nerves' | Mental health | UKBB00000799 | 7.47 |
| 994 | NPDC1/PTGDS ratio | GCST90315549 | 7.47 |
| 995 | EBAG9/FKBP5 ratio | GCST90314564 | 7.45 |
| 996 | ITGB1BP2/WASF1 ratio | GCST90315224 | 7.44 |
| 997 | PXN levels | GCST90470396 | 7.44 |
| 998 | Dorsalgia | FING00000472 | 7.42 |
| 999 | N6,N6-dimethyllysine levels in chronic kidney disease | GCST90257529 | 7.40 |
| 1000 | APP/HBEGF ratio | GCST90313324 | 7.40 |